Side Effects of Blood Thinners, Diabetes Drugs Are Leading Causes of ER Visits Due to Medications: Study

Xarelto, Warfarin and other blood thinners are the leading cause of hospital visits due to drug side effects, leading to calls for closer monitoring

New research suggests many common prescription and over-the-counter medications used to treat patients for diabetes and heart conditions are resulting in the most hospitalization due to adverse or unintentional drug side effects, which may cause serious and potentially life threatening harm.

In a new study published in The Journal of the American Medical Association (JAMA) on October 5, researchers identified several classes of medications associated with the highest rate of emergency room visits, urging the medical community to closely monitor patients among the high-risk treatment groups.

The study was led by U.S. Centers for Disease Control and Prevention (CDC) researchers, who reviewed nearly 97,000 cases of adverse events involving both prescription and over-the-counter medications reported through the National Electronic Injury Surveillance System–Cooperative Adverse Drug Event Surveillance Project from 2017 through 2019.

According to the findings, blood thinners like warfarin (Coumadin), Xarelto and other anti-coagulants, which are commonly prescribed to patients to reduce the risk of heart attack and stroke, are the leading cause of emergency room visits across all patient age ranges, accounting for 38.6% of all hospitalizations.

The rate of hospitalization involving blood thinner side effects significantly increased for individuals 65 years of age and older.

Across all age groups, adverse effects of insulin were the second leading cause of emergency department visits, accounting for 7,107 incidents, followed by psychiatric drugs, antibiotics and the over-the-counter pain relievers ibuprofen, sold under brand names like Motrin, and acetaminophen, the active ingredient in Tylenol.

Researchers noted the age of the patient, type of use, and whether therapeutic and non-therapeutic abuse played a significant role in the amount of emergency department visits.

The majority of emergency department visits involving blood thinners, insulin and antibiotics were classified as unintended consequences of therapeutic use, while nearly 89% of emergency room visits for drugs such as analgesics, sedatives and antidepressants were classified as non-therapeutic cases of abuse.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Importance of Monitoring for Bleeding Problems With Blood Thinners

To address the hospitalizations caused by drug side effects, researchers recommend the medical community closely monitor patients categorized in these high risks groups, especially for those being prescribed blood thinners such as Pradaxa, Eliquis and Xarelto, which have been linked to patients suffering severe bleeding events, hemorrhages, gastrointestinal bleeding, strokes and death.

Xarelto, Pradaxa and Eliquis are all part of a new class of anticoagulants used to reduce the risk of blood clots and strokes, particularly among patients with atrial fibrillation.

While all anticoagulants carry a risk of bleeding, the blood thinning effects of warfarin can be reversed with a combination of vitamin K and plasma. When first approved, the new class of drugs had no such reversal agent, making it difficult for doctors to stop bleeding events before serious injury or death occur.

As a result of thousands of patient’s injuries and deaths linked to Xarelto, Pradaxa and Eliquis, lawsuits have been filed alleging the manufactures withheld important safety information about the bleeding risk and the lack of an effective reversal agent. In addition, claims indicate that risk of injury outweighs any potential benefit provided by the drugs, making the drug unreasonably dangerous and defective as it was originally formulated.

Boehringer Ingelheim reached a Pradaxa settlement agreement with most plaintiffs in 2014. A global Xarelto settlement was reached in March 2019, resolving nearly all claims.

1 Comments

  • FredrickJanuary 29, 2024 at 11:55 am

    I have been on Xarelto since July of 2023. When they prescribe this the medication for me they did not tell me about any other side effects. I just recently read about it and I could possibly die from uncontrollable bleeding. Most hospitals don't even carry the antidote and those that do have an extremely high rate of death after administering the antidote. If I had known that I would have asked t[Show More]I have been on Xarelto since July of 2023. When they prescribe this the medication for me they did not tell me about any other side effects. I just recently read about it and I could possibly die from uncontrollable bleeding. Most hospitals don't even carry the antidote and those that do have an extremely high rate of death after administering the antidote. If I had known that I would have asked them to keep me on coumadin

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted yesterday)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted yesterday)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.

Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant
Abbott Laboratories Faces Jury Trial Over Claims Similac Caused NEC For Premature Infant (Posted 2 days ago)

Following a $60 million verdict in a similar lawsuit earlier this year, trial is underway involving claims brought by an Illinois mother, whose premature daughter developed NEC from Similac, alleging that Abbott failed to warn parents and medical staff of the devastating risks associated with the cow's milk-based formula.